CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Financial Statements and Exhibits
Item 9.01.
Financial Statements and Exhibits
| (d) |
Exhibit No. |
Description. |
| 99.1 | Investor Presentation. |
CytoDyn Inc. Exhibit
EX-99.1 2 d560026dex991.htm EX-99.1 EX-99.1 ® www.cytodyn.com First self-administered antibody therapy for HIV in late-stage clinical development March 2018 PRO 140 Exhibit 99.1 www.cytodyn.com This presentation includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn’s intentions,…
To view the full exhibit click here
About CytoDyn Inc. (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.
